You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Staar Surgical (STAA) Reports Q1 Earnings: What Key Metrics Have to Say
Read MoreHide Full Article
Staar Surgical (STAA - Free Report) reported $77.36 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 5.2%. EPS of $0.06 for the same period compares to $0.18 a year ago.
The reported revenue represents a surprise of +0.33% over the Zacks Consensus Estimate of $77.1 million. With the consensus EPS estimate being $0.05, the EPS surprise was +20.00%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Staar Surgical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Net Geographic sales- United States: $4.94 million versus the two-analyst average estimate of $4.20 million. The reported number represents a year-over-year change of +8.4%.
Net Geographic sales- Other International: $23.42 million versus $19.39 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2% change.
Net Geographic sales- China: $38.55 million compared to the $38.08 million average estimate based on two analysts. The reported number represents a change of +9.9% year over year.
Net Geographic sales- Japan: $10.46 million versus the two-analyst average estimate of $10.66 million. The reported number represents a year-over-year change of -4.4%.
Net sales- ICLs: $77.15 million versus $72.31 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.
Shares of Staar Surgical have returned -7.1% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Staar Surgical (STAA) Reports Q1 Earnings: What Key Metrics Have to Say
Staar Surgical (STAA - Free Report) reported $77.36 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 5.2%. EPS of $0.06 for the same period compares to $0.18 a year ago.
The reported revenue represents a surprise of +0.33% over the Zacks Consensus Estimate of $77.1 million. With the consensus EPS estimate being $0.05, the EPS surprise was +20.00%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Staar Surgical performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Geographic sales- United States: $4.94 million versus the two-analyst average estimate of $4.20 million. The reported number represents a year-over-year change of +8.4%.
- Net Geographic sales- Other International: $23.42 million versus $19.39 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2% change.
- Net Geographic sales- China: $38.55 million compared to the $38.08 million average estimate based on two analysts. The reported number represents a change of +9.9% year over year.
- Net Geographic sales- Japan: $10.46 million versus the two-analyst average estimate of $10.66 million. The reported number represents a year-over-year change of -4.4%.
- Net sales- ICLs: $77.15 million versus $72.31 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +9.2% change.
View all Key Company Metrics for Staar Surgical here>>>Shares of Staar Surgical have returned -7.1% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.